T he physical health of patients with schizophrenia has attracted increasing attention during the last 10 years, with around 60% of the excess mortality related to natural causes and only 40% to suicide and other unnatural causes. 1 To date, guidelines from national psychiatric associations, independent bodies, and regulatory agencies have focused on the reduction of selected cardiovascular risk factors. What has been absent is specific attention to cancer.
Mortality rates in schizophrenia remained very high from 1926 to 2000, ranging from an SMR of 1.51 to 3.34. 2 The most recent data derive from a 25-year prospective record linkage study 3 in the United Kingdom, from 1981 to 2006, which reported an SMR of 2.89. The contribution of cancer to this elevated mortality has been little discussed until recently 4, 5 despite clear evidence that SMRs for neoplastic diseases are significantly elevated in schizophrenia and there remain 2 further questions. First, what is the incidence of cancer and specific cancers in schizophrenia? Second, what is the relation between incidence and mortality rates? Some dissonance in this relation could be expected should any covert or overt prejudice exist in either providing treatment or delaying such treatment. There is already recognition that for cardiovascular admissions, treatments, and medications, schizophrenia patients are significantly disadvantaged, compared with a general population, and that this has shown no sign of change during the last decade. 6, 7 It is also time to review the current evidence for the concept proposed in 1909 by The Board of Control of the Commissioners of Lunacy for England and Wales 8 that there may be a decreased incidence of cancer in people with schizophrenia.
We have focused our review predominantly on recent data as many of the earlier studies, particularly those finding reduced cancer rates, base their findings on proportionate mortality rates that are currently not regarded as an appropriate methodology. 9 Since 1977, 10 the World Health Organization has undertaken a project on cancer incidence in schizophrenia 9 designed to overcome some of the original methodological issues. They proposed to conduct cohort studies in countries where psychiatric and cancer registries existed using record linkage techniques and to report the incidence data rather than mortality data. This is evidenced in Denmark where the Danish Cancer Registry has been in existence since 1943 and contains data on 95% to 99% of all diagnosed cancer cases, 10 and which could be matched with up to 5 other sources of registered data, including the Central Psychiatric Register, which has existed in Denmark since 1953. 9
Mortality Rates in Schizophrenia for Cancer
There are 3 separate metrics that need clarification when examining mortality rates in schizophrenia. First, what is the total SMR for neoplastic disorders in its totality, compared with relevant age-matched and otherwise appropriate populations? Second, what are the SMRs for individual cancers? Third, what percentage of deaths in schizophrenia is attributable to cancer? The latter metric may be the most relevant in informing development of any guidelines.
SMRs for Neoplastic Disorders
SMRs for neoplastic disorders have been determined from meta-analysis, 11 retrospective epidemiologic database studies, 12 and prospective mortality studies. 5 SMRs for death from neoplastic diseases are, in general, elevated (Table 1) . However, this is a recent finding, given that, in a 1992 study, which used record linkage data from 3 countries, Gulbinat et al 9 reported that death rates were increased for almost all causes of death except cancer. The Saha et al 11 meta-analysis reported a median SMR for neoplastic diseases elevated at 1.37, compared with 1.79 for cardiovascular disease. However, it is critical to understand that neither age of the cohort nor person-years follow-up were stated, 11 and these facets have implications when looking for robust conclusions on cancer mortality. 13 One of the largest cohort studies, 12 of 17 600 schizophrenia subjects during 28 years, found significantly elevated MRRs for malignant neoplasms of 1.24 and 1.32, in males and females, respectively. The cohort was relatively young, with a maximal cohort age of 48 years at the end of follow-up, and this may have led to lower cancer mortality than expected. An increased mortality rate has been reported by other studies 3, 14 from the United Kingdom and Denmark ( Table 1 ).
The reporting of cohort age at study conclusion may be a critical confounder. Populations where patients are not followed-up to an age when cancer incidence and mortality is maximal may underestimate cancer mortality and incidence, making SMRs complex to interpret. An example is breast cancer, where 80% of incident cases arise in the cohort aged 51 years and older 13, 15 data are similar for lung cancer. 16 The recent Danish data show clearly the relation between increasing age and cancer incidence. [14] [15] [16] Fewer data are published on SMRs for individual cancers. The Danish study 14 reported the relative survival for all cancer types but not the actual case numbers, which makes interpretation complex. Significantly decreased survival rates were reported for cancers of the rectum, breast, cervix, and ovary at 1 year in females, but only for cervix at 5 years. Paradoxically, increased survival was noted for cancers of the mouth and pharynx in women. In men, decreased 1-year survival was reported for rectum, lung, and testis cancers, and for lung cancer at 5 years. 14 More detailed data are reported in other publications on this same cohort in which, for lung cancer, there were 142 males and 149 females, with 5-year survival rates of only 5% in males and 6% in females (compared with 8% and 9% in the general population). 16 Five-year survival rates in breast cancer were more encouraging, with 5-year survival rates of 74%, compared with 79% for the general population survival (nonsignificant). 15 Methodologically prospective studies have advantages over retrospective epidemiologic-based database studies. An example is an 11-year prospective mortality study in 3470 schizophrenia patients (1993 to 2003). 5 Cancer was the second most frequent cause of mortality (SMR 1.5; 95% CI 1.2 to 1.9), with 50% of the cancer in males being lung (SMR 2.2; 95% CI 1.6 to 3.3) and 39% of the cancer in females being breast (SMR 2.8; 95% CI 1.6 to 4.9). There were 2 significant baseline predictors of death from lung cancer: duration of smoking and age 39 years and older. The SMR for lung cancer was also found to be significantly elevated, SMR 2.65, in the recent UK cohort study. 3
What Percent of Deaths Is Attributable to Cancer?
The seemingly simple question of what do schizophrenia patients actually die from is one of the more complex and arguably unanswered questions at present. Cause of death in clinical studies relates to many varied factors that include the age of the cohort, the length and decade of follow-up, and the size of the patient population. Cancer rates will only be measured accurately if the cohort is aged 51 years and older at onset of follow-up (when most cancer is diagnosed). [13] [14] [15] [16] Despite these complexities, the contribution of cancer to mortality in non-FEP studies is consistent at between 16% to 21% of deaths. The rate of around 16% to 21% is not dissimilar to cardiovascular disease deaths. 2, 4, 5, [17] [18] [19] In FEP it was lowered at 6%. 20 In 5 of the 6 studies, the cohort entry age was 49 years or younger. An excess mortality in cohorts who might be too young to develop cancer raises the possibility that patients with schizophrenia present with cancer at younger ages than the general population. For example, patients with schizophrenia may be more susceptible to risk factors, such as smoking and prolactin, that may bring forward the temporal onset of cancer. A further aspect that cannot be ignored is that of prejudice against patients with schizophrenia, in terms of either late diagnosis or incomplete treatments, that would also explain the excess mortality through cancer. Certainly evidence exists in psychiatric populations that mortality rates are seemingly too high when contrasted with incidence rates. Recent data from Nova Scotia, where there is a universal health care system (hence private insurance does not play a role), found significant elevation of cancer mortality by 72% in males and 59% in females that could not be explained by cancer incidence rates. 21 The total cancer IRR of 1.21 was significantly less than the MRR of 1.72, with similar data available from Western Australia. 22
What Is the Incidence of Cancer in Schizophrenia?
The debate over whether cancer is decreased in schizophrenia has been ongoing for more than a century since the Commissioners of Lunacy in 1909 advanced this hypothesis. 8 Numerous datasets have been published speculating that cancer may be decreased and suggesting reasons. Theories have included a protective effect of excess dopamine, enhanced natural killer cell activity, an increase in the rate of apoptosis, and various effects of antipsychotics. 8 However, it is only now that this question can be addressed systematically through record linkage. There are 2 aspects to carefully define. First, overall cancer incidence is not the correct metric to measure as there are numerous cancer types, each with their own causes. Rather than measure cancer as an entity, it may be more appropriate to consider individual cancer types. Second, there are 2 ways to present incidence rates-either as crude or as adjusted. Adjustment presumes that the relevant confounders are both known and measured. For most cancers, all relevant confounders in schizophrenia are unknown and often unmeasured in the databases from which incidence data derive. A recent meta-analysis reported an increased incidence of lung cancer in schizophrenia that decreased below that expected when adjusted for smoking. However, data on smoking were historical and had been published elsewhere and the necessary adjustment methods may be complex. 23 There remains dissonance in the reported data over whether the incidence of total cancer is lowered, similar, or elevated. The only meta-analysis of cancer incidence rates reported no difference, compared with general population samples (SIR 1.05). 23 A large Danish study 10 from 1957 to 1984 following 6168 patients with schizophrenia actually found a significant reduction (IRR 0.90) when age-and sex-adjusted, especially in males (IRR 0.76). By contrast, a later nationwide population-based register study 14 of people with schizophrenia from Denmark reported that the incidence of cancer was significantly increased by almost 50% in males and females (adjusted IRR 1.47 men and 1.40 women). For individual cancers, there were significant increases for lung (adjusted IRR 3.03 men and 2.51 women), breast (adjusted IRR 1.18 women) and cervix (adjusted IRR 1.35 women) whereas prostate cancer was significantly decreased (adjusted IRR 0.59). The same study also reported that cancer incidence increased with lower education and income; however, for breast and prostate cancer, the association was inverse. This provides further evidence that some undefined factors, such as prolactin, may be relevant regarding the elevated incidence of breast cancer in schizophrenia. 13, 19, 24, 25 This issue is discussed further in the next section.
A further intriguing finding from the only meta-analysis of cancer incidence in schizophrenia was that although the overall cancer rate was indeed the same as it was for the general population, it was lower in their siblings (SIR 0.89; 95% CI 0.84 to 0.94) and parents (SIR 0.90; 95% CI 0.88 to 0.93). 23
Breast Cancer Incidence in Schizophrenia
Existing studies have provided a plethora of views on whether incidence is raised. The only systematic review of breast cancer incidence in schizophrenia concluded that the incidence of breast cancer was increased and possibly substantially so, and has gone some way to explaining the dissonance in study results. 13 Data were available from more than 6000 female schizophrenia patients from 13 studies reporting data from 1986 to 2008. However, the results were widely discrepant, ranging from a 52% increase in risk to a 40% decrease, with only 6 of the 13 studies reporting an increased or a marginally increased rate of breast cancer. Some of these data had been included in a previous meta-analysis that also reported increased risk (SIR 1.12; 95% CI 1.02 to 1.23). 23 However, what the systematic review allowed was a closer look at the reasons for this dissonance. Three quality markers had a strong relation to study outcome-studies with more than100 cases of breast cancer or 100 000 person/years follow-up, and most importantly, studies in which subjects aged 51 years and older had been followed for a significant time. The likelihood of an increased incidence of breast cancer in schizophrenia related to these methodological issues. Further, few of the studies identified and adjusted for any putative confounders and it may be relevant that the only study to adjust for smoking, body mass index, and SES, gave the single largest increased incidence of 52%. The mean age of 61 years at diagnosis may also be important. 26 Many factors are associated with an increased risk of breast cancer: increasing social advantage, decreased level of schooling, unemployment, retirement, urbanicity, single or divorced, and history of admission for a psychiatric disorder. 15 These are all factors relevant to a schizophrenia population.
Another aspect to consider is the degree of overlap between database linkage studies from the same country. For example, although 2 of the studies 27,28 reported a significantly lower risk of breast cancer (SIR 0.60 and 0.63), these studies were both from Israel and appeared to have significant cohort overlap. A similar situation was apparent with the 5 studies reported from Denmark between 1986 and 2005, giving widely discrepant results. 10, [29] [30] [31] [32] Some of these studies had significant age limits on their inclusion cohorts; for example, first-hospitalization cohorts 32 in which breast cancer would have a significantly lower incidence than in an older cohort. 15 A meta-analytic analysis on these studies could thus be viewed as complex to interpret, requiring determination of the degree of weighting and inclusion of studies. 23 It may be salient that the 2 most recent breast cancer incidence studies from Denmark using large study populations both found significantly elevated rates of breast cancer. 15 
Lung Cancer Incidence in Schizophrenia
The data on lung cancer are equivocal. Crude rates are significantly elevated (SIR 1.31; 95% CI 1.01 to 1.71); however, when adjusted for historical rates of smoking, they are significantly lower than in the general population (SIR 0.69). 23 A similar reduced risk of respiratory cancer was reported in a large UK nested, case-control study 26 using 454 general practices contributing to the QResearch database (OR 0.53; 95% CI 0.34 to 0.85) that adjusted for multiple illnesses and medications but, importantly, smoking and SES. However, compared with the Catts meta-analysis, the unadjusted rate was not elevated (OR 0.71; 95% CI 0.46 to 1.11). Data from Denmark in 1989 also reported a significantly reduced rate of lung cancer (IRR 0.33; P < 0.001) 10 This reduced rate of lung cancer incidence is both curious and controversial in light of the increased rate of smoking and increased amount smoked by subjects with schizophrenia. 3, 34 Smoking is essentially the single cause of lung cancer and is etiologically linked with many other cancers. In a recent UK cohort followed from 1981 to 2006, 73% were smokers at study outset, 3 more than twice the general population rate of 35%.
However, not all data are consistent and other data report elevated rates of lung cancer. A large record linkage study 35 from Finland in patients with schizophrenia (n = 27 000) reported an unadjusted SIR of 2.17 (95% CI 1.78 to 2.60), a study 36 from Israel reported as unadjusted of SIR 1.38, and the recent large study 16 from Denmark, which adjusted for calendar year, age, education, and disposable income, found an IRR of 3.03 (95% CI 2.57 to 3.58) in males and 2.51 (95% CI 2.14 to 2.94) in females; all these data were significant when compared with a relevant general population of that country. Finally, a few studies 8, 33 report no difference with a general population.
In summary, there does appear to be a probable reduction in lung cancer in people with schizophrenia when adjusted for smoking.
Incidence at Other Cancer Sites
For other cancers there are discrepant results relating to many of the factors discussed above. The UK nested, case-control study 26 reported significantly elevated risk of colon cancer in the schizophrenia population (OR 2.9; 95% CI 1.85 to 4.57) that increased further (OR 4.08; 95% CI 2.43 to 6.84) in the cohort receiving antipsychotics, though rectal and gastroesophageal cancers were no different to general population. Also of relevance in this population is that the median age of diagnosis of colon cancer was 72 years. These data contrast with previous data that tend to report no difference. 8, 30, 35 However, the age of the Goldacre et al 8 cohort was young in terms of cancer incidence, with a modal age group of 25 to 29 years and an average follow-up period of 12.6 years. The Catts meta-analysis that subsequently included 4 studies found a reduced risk of colon cancer (SIR 0.84; 95% CI 0.70 to 1.00). 23 In the UK study, 26 which allowed for significant adjustments, prostate cancer was reduced before adjustment (OR 0.54) but nonsignificant after adjustment (OR 0.59; 95% CI 0.59 to 1.05). This is in agreement with the meta-analysis reporting a significant reduction (SIR 0.59; 95% CI 0.48 to 0.73). 23 Other cancers, such as bladder cancer, also appear to be reduced when adjusted for smoking (SIR 0.63 [95% CI not stated]). 23 Some comment has to be made about the low number of cancer cases in many of these studies, which exemplifies the complexity of defining the cancer incidence in a specific site. A large UK cohort linkage study 8 that included 486 incident cancer patients contained 88 lung and 80 breast cancer patients, but only 4 patients with testicular cancer and 2 with melanoma. However, these latter 2 patients allowed for a statistically significant decrease to be reported (ARR 0.2; 95% CI 0.02 to 0.74). Reduced risks of skin cancer, and specifically malignant melanoma, are reported with meta-analysis finding a lowered risk of SIR 0.71 (95% CI 0.57 to 0.87) for malignant melanoma. 23 Some evidence to support a protective effect of schizophrenia against cancer comes from meta-analysis of studies measuring cancer incidence in the parents and siblings of patients with schizophrenia and finds a significantly reduced risk in both parents (SIR 0.90; 95% CI 0.88 to 0.93) and siblings (SIR 0.89; 95% CI 0.84 to 0.94), 23 although the data remain inconclusive. [35] [36] [37] 
Conclusion
The relation between cancer and schizophrenia poses clinical and academic questions. There is little doubt that cancers, especially breast and lung, are increased in people with schizophrenia, and that there are similar numbers of cancer deaths and cardiovascular deaths. However, when adjusted for the critical confounder of smoking, lung cancer rates may be lower than expected and this provides some evidence to support an inherent lower risk of cancer in schizophrenia. Cancer rates in first-degree relatives may also be lower than those in patients. The precise confounders are simply not known and so cannot be adjusted for in our current epidemiologic database. For many cancers, other than breast, there is a correlation between glucose level and cancer risk. 38 This too is a conundrum as schizophrenia the illness is cited as an independent risk factor for diabetes. The link between prolactin elevation and breast cancer in the general population is firmly established but we await confirmation in schizophrenia. However, a concern remains as to whether the true incidence of cancer is correctly known in a schizophrenia population, owing to a failure to screen and diagnose cancer.
There will never be a definitive single study to provide all the answers and we need to lean heavily on systematic review as an analytic tool. For this to be accurate, there needs to be consistent and helpful reporting of the basic parameters in any cancer paper. We are left with the thought that the Commissioners of Lunacy in 1909 may have been correct in their assumption that schizophrenia may provide some protection against cancer. While we await answers, we should at least ensure that rates of screening patients with schizophrenia for cancers, such as breast and prostate, where cure is a probable outcome, match those screening rates for the general population. 
Résumé : La schizophrénie et le cancer : en 2010, comprenons-nous le lien?
Objectif : Ces dernières années, il y a eu une pléthore de données sur la mortalité par cancer et l'incidence rapportées dans la schizophrénie. Malgré cela, les lignes directrices sur la schizophrénie mettent peu l'accent sur le cancer. De plus, il a été suggéré que la schizophrénie puisse offrir une protection inhérente contre le cancer. Le but de cette étude est d'établir, à l'aide des données récentes, les taux d'incidence et de mortalité par cancer dans la schizophrénie.
Méthode : Nous avons repéré les revues systématiques et les méta-analyses, et mené une recherche au moyen des termes « schizophrénie » et « néoplasm » dans les « Medical Subject Headings ».
Résultats : Les taux d'incidence et de mortalité par cancer dans la schizophrénie sont accrus, comparativement aux populations générales pertinentes. Les données ne sont pas uniformément rapportées et l'âge des cohortes tend à être jeune pour l'incidence du cancer. Malgré le jeune âge des cohortes, l'incidence des principaux cancers -poumon et sein -est substantiellement accrue. Les variables confusionnelles ne sont pas souvent mesurées dans les bases de données épidémiologiques. Lorsque le cancer du poumon est ajusté pour les taux de tabagisme, il semble que le risque de cancer du poumon soit plus faible que prévu, ce qui pourrait contribuer à soutenir l'hypothèse d'un risque de cancer réduit de façon inhérente. Il peut également y avoir une dissonance entre les taux d'incidence et de mortalité qui suggère un préjugé s'exerçant lors du diagnostic ou du traitement de ces patients vulnérables.
Conclusion :
Une seule étude définitive de la schizophrénie et du cancer n'est pas faisable et dans le futur la recherche dépendra fortement des revues systématiques et des méta-analyses. Les chercheurs devraient rapporter des données qui incluent l'âge et les données de suivi et le chevauchement des cohortes. Le cancer représente presque l'équivalent de la mortalité par maladie cardiovasculaire.
